Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC

被引：58
作者：
Medema, Rene H. [1 ,2 ]
Lin, Chia-Chi [3 ]
Yang, James Chih-Hsin [3 ,4 ,5 ]
机构：
[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands
[3] Natl Taiwan Univ, Dept Oncol, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan
来源：
CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 20期
关键词：
CELL LUNG-CANCER; PHASE-III TRIAL; SMALL INTERFERING RNA; CHEMOTHERAPY REGIMENS; TUMOR-GROWTH; BI; 2536; PLK1; MUTATIONS; DOCETAXEL; CARBOPLATIN;
D O I：
10.1158/1078-0432.CCR-11-0541
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cytotoxic platinum-doublet chemotherapy that includes antimitotic agents is a current standard of care in advanced non-small cell lung cancer (NSCLC). Microtubule-targeting antimitotics, taxanes, and Vinca alkaloids are effective anticancer therapeutics that affect both dividing and nondividing cells. A new generation of antimitotic agents that target regulatory proteins-mitotic kinases and kinesins-has the potential to overcome the limitations related to the role of tubulin in nondividing cells that are associated with traditional antimitotics. This review concentrates on Polo-like kinase 1, a key regulator of mitosis, outlines a rationale for its development as an anticancer target, and discusses data from preclinical and clinical studies of Plk1 inhibitors with a particular focus on NSCLC. Clin Cancer Res; 17(20); 6459-66. (C) 2011 AACR.
引用
收藏
页码：6459 / 6466
页数：8
相关论文
共 63 条
  • [41] Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC
  • [42] Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
    Rosell, Rafael
    Moran, Teresa
    Queralt, Cristina
    Porta, Rut
    Cardenal, Felipe
    Camps, Carlos
    Majem, Margarita
    Lopez-Vivanco, Guillermo
    Isla, Dolores
    Provencio, Mariano
    Insa, Amelia
    Massuti, Bartomeu
    Luis Gonzalez-Larriba, Jose
    Paz-Ares, Luis
    Bover, Isabel
    Garcia-Campelo, Rosario
    Angel Moreno, Miguel
    Catot, Silvia
    Rolfo, Christian
    Reguart, Noemi
    Palmero, Ramon
    Miguel Sanchez, Jose
    Bastus, Roman
    Mayo, Clara
    Bertran-Alamillo, Jordi
    Angel Molina, Miguel
    Javier Sanchez, Jose
    Taron, Miquel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) : 958 - U38
  • [43] BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
    Rudolph, Dorothea
    Steegmaier, Martin
    Hoffmann, Matthias
    Grauert, Matthias
    Baum, Anke
    Quant, Jens
    Haslinger, Christian
    Garin-Chesa, Pilar
    Adolf, Guenter R.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (09) : 3094 - 3102
  • [44] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Sandler, Alan
    Gray, Robert
    Perry, Michael C.
    Brahmer, Julie
    Schiller, Joan H.
    Dowlati, Afshin
    Lilenbaum, Rogerio
    Johnson, David H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) : 2542 - 2550
  • [45] Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Schiller, JH
    Harrington, D
    Belani, CP
    Langer, C
    Sandler, A
    Krook, J
    Zhu, JM
    Johnson, DH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) : 92 - 98
  • [46] The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy Results from an Open-Label, Randomized Phase II Clinical Trial
    Sebastian, Martin
    Reck, Martin
    Waller, Cornelius F.
    Kortsik, Cornelius
    Frickhofen, Norbert
    Schuler, Martin
    Fritsch, Holger
    Gaschler-Markefski, Birgit
    Hanft, Gertraud
    Munzert, Gerd
    von Pawel, Joachim
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) : 1060 - 1067
  • [47] EGFR tyrosine kinase inhibitors in lung cancer: An evolving story
    Sequist, Lecia V.
    Lynch, Thomas J.
    [J]. ANNUAL REVIEW OF MEDICINE, 2008, 59 : 429 - 442
  • [48] Erlotinib in previously treated non-small-cell lung cancer
    Shepherd, FA
    Pereira, JR
    Ciuleanu, T
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Campos, D
    Maoleekoonpiroj, S
    Smylie, M
    Martins, R
    van Kooten, M
    Dediu, M
    Findlay, B
    Tu, DS
    Johnston, D
    Bezjak, A
    Clark, G
    Santabárbara, P
    Seymour, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) : 123 - 132
  • [49] Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    Shepherd, FA
    Dancey, J
    Ramlau, R
    Mattson, K
    Gralla, R
    O'Rourke, M
    Levitan, N
    Gressot, L
    Vincent, M
    Burkes, R
    Coughlin, S
    Kim, Y
    Berille, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) : 2095 - 2103
  • [50] Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1
    Spänkuch, B
    Matthess, Y
    Knecht, R
    Zimmer, B
    Kaufmann, M
    Strebhardt, K
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11): : 862 - 872
1234567